Browsing Tag
Samsung Biologics Co. Ltd.
1 post
Samsung Biologics is not just buying PolyPeptide. It is buying into the GLP-1 supply chain
Samsung Biologics plans to acquire PolyPeptide for CHF 1.46 billion. Read how the deal targets peptide CDMO capacity and GLP-1 manufacturing demand.